-
1
-
-
41949111045
-
Acute promyelocytic leukemia: From highly fatal to highly curable
-
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111:2505-2515.
-
(2008)
Blood
, vol.111
, pp. 2505-2515
-
-
Wang, Z.Y.1
Chen, Z.2
-
2
-
-
33646386643
-
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
-
Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107:3469-3473.
-
(2006)
Blood
, vol.107
, pp. 3469-3473
-
-
Estey, E.1
Garcia-Manero, G.2
Ferrajoli, A.3
-
3
-
-
77949889670
-
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
-
Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010; 28:1047-1053.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1047-1053
-
-
Gore, S.D.1
Gojo, I.2
Sekeres, M.A.3
-
4
-
-
62549083523
-
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
-
Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106:3342-3347.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 3342-3347
-
-
Hu, J.1
Liu, Y.F.2
Wu, C.F.3
-
5
-
-
84880287051
-
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
-
Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013; 369:111-121.
-
(2013)
N Engl J Med
, vol.369
, pp. 111-121
-
-
Lo-Coco, F.1
Avvisati, G.2
Vignetti, M.3
-
6
-
-
0033890197
-
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
-
European APL group
-
Fenaux P, Chevret S, Guerci A, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14:1371-1377.
-
(2000)
Leukemia
, vol.14
, pp. 1371
-
-
Fenaux, P.1
Chevret, S.2
Guerci, A.3
-
7
-
-
0037115195
-
All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
-
Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100:4298-4302.
-
(2002)
Blood
, vol.100
, pp. 4298-4302
-
-
Tallman, M.S.1
Andersen, J.W.2
Schiffer, C.A.3
-
8
-
-
0034663162
-
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
-
Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247-1253.
-
(2000)
Blood
, vol.96
, pp. 1247-1253
-
-
Sanz, M.A.1
Lo Coco, F.2
Martin, G.3
-
9
-
-
74049115852
-
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG
-
Lengfelder E, Haferlach C, Saussele S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009; 23:2248-2258.
-
(2009)
Leukemia
, vol.23
, pp. 2248-2258
-
-
Lengfelder, E.1
Haferlach, C.2
Saussele, S.3
-
10
-
-
59149089411
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
-
Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504-510.
-
(2009)
J Clin Oncol
, vol.27
, pp. 504-510
-
-
Ravandi, F.1
Estey, E.2
Jones, D.3
-
11
-
-
84948978098
-
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial
-
Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16:1295-1305.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1295-1305
-
-
Burnett, A.K.1
Russell, N.H.2
Hills, R.K.3
-
12
-
-
0030825408
-
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
-
Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups
-
Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-1021.
-
(1997)
Blood
, vol.90
, pp. 1014-1021
-
-
Mandelli, F.1
Diverio, D.2
Avvisati, G.3
-
13
-
-
0033230342
-
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia
-
PETHEMA group
-
Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94:3015-3021.
-
(1999)
Blood
, vol.94
, pp. 3015-3021
-
-
Sanz, M.A.1
Martin, G.2
Rayon, C.3
-
14
-
-
0033564337
-
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
-
Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93:4131-4143.
-
(1999)
Blood
, vol.93
, pp. 4131-4143
-
-
Burnett, A.K.1
Grimwade, D.2
Solomon, E.3
-
15
-
-
0028999532
-
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
-
Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85:2643-2653.
-
(1995)
Blood
, vol.85
, pp. 2643-2653
-
-
Degos, L.1
Dombret, H.2
Chomienne, C.3
-
16
-
-
77952300646
-
Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation
-
Breccia M, Latagliata R, Cannella L, et al. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2010; 95:853-854.
-
(2010)
Haematologica
, vol.95
, pp. 853-854
-
-
Breccia, M.1
Latagliata, R.2
Cannella, L.3
-
17
-
-
10744220024
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group
-
Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237-1243.
-
(2004)
Blood
, vol.103
, pp. 1237-1243
-
-
Sanz, M.A.1
Martin, G.2
Gonzalez, M.3
-
18
-
-
77958499078
-
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group
-
Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116:3171-3179.
-
(2010)
Blood
, vol.116
, pp. 3171-3179
-
-
Lo-Coco, F.1
Avvisati, G.2
Vignetti, M.3
-
19
-
-
84887590193
-
Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL)
-
Park S, Lee SJ, Kim K, et al. Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). Int J Hematol 2013; 97:388-396.
-
(2013)
Int J Hematol
, vol.97
, pp. 388-396
-
-
Park, S.1
Lee, S.J.2
Kim, K.3
-
20
-
-
84892541353
-
Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients
-
Breccia M, De Propris MS, Minotti C, et al. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res 2014; 38:194-197.
-
(2014)
Leuk Res
, vol.38
, pp. 194-197
-
-
Breccia, M.1
De Propris, M.S.2
Minotti, C.3
-
21
-
-
84921806223
-
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells
-
Breccia M, De Propris MS, Stefanizzi C, et al. Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. Ann Hematol 2014; 93:1819-1823.
-
(2014)
Ann Hematol
, vol.93
, pp. 1819-1823
-
-
Breccia, M.1
De Propris, M.S.2
Stefanizzi, C.3
-
22
-
-
24944447981
-
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia
-
Kuchenbauer F, Schoch C, Kern W, et al. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 2005; 130:196-202.
-
(2005)
Br J Haematol
, vol.130
, pp. 196-202
-
-
Kuchenbauer, F.1
Schoch, C.2
Kern, W.3
-
23
-
-
84855577993
-
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
-
Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012; 119:49-54.
-
(2012)
Blood
, vol.119
, pp. 49-54
-
-
Breccia, M.1
Mazzarella, L.2
Bagnardi, V.3
-
24
-
-
0037188535
-
Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy
-
Gu BW, Xiong H, Zhou Y, et al. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci USA 2002; 99:7640-7645.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 7640-7645
-
-
Gu, B.W.1
Xiong, H.2
Zhou, Y.3
-
25
-
-
33645324761
-
PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients
-
Melo RA, de Vasconcellos JF, Melo FC, et al. PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin Lab Haematol 2006; 28:126-129.
-
(2006)
Clin Lab Haematol
, vol.28
, pp. 126-129
-
-
Melo, R.A.1
De Vasconcellos, J.F.2
Melo, F.C.3
-
26
-
-
84889850349
-
FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: Longterm follow-up analysis
-
Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: longterm follow-up analysis. Haematologica 2013; 98:e161-e163.
-
(2013)
Haematologica
, vol.98
, pp. e161-e163
-
-
Breccia, M.1
Loglisci, G.2
Loglisci, M.G.3
-
27
-
-
84859144177
-
Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
-
Hong SD, Kim YK, Kim HN, et al. Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients. Korean J Hematol 2011; 46:24-30.
-
(2011)
Korean J Hematol
, vol.46
, pp. 24-30
-
-
Hong, S.D.1
Kim, Y.K.2
Kim, H.N.3
-
28
-
-
84955659957
-
A molecular risk score integrating BAALC ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia
-
[Epub ahead of print]
-
Hecht A, Nowak D, Nowak V, et al. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leuk Res 2015. [Epub ahead of print]
-
(2015)
Leuk Res
-
-
Hecht, A.1
Nowak, D.2
Nowak, V.3
-
29
-
-
84931038270
-
Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia
-
Albano F, Zagaria A, Anelli L, et al. Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. Oncotarget 2015; 6:13269-13277.
-
(2015)
Oncotarget
, vol.6
, pp. 13269-13277
-
-
Albano, F.1
Zagaria, A.2
Anelli, L.3
-
30
-
-
84940959459
-
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy
-
Lou Y, Ma Y, Suo S, et al. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res 2015; 39:938-944.
-
(2015)
Leuk Res
, vol.39
, pp. 938-944
-
-
Lou, Y.1
Ma, Y.2
Suo, S.3
-
31
-
-
84865427746
-
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
-
Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120:1570-1580.
-
(2012)
Blood
, vol.120
, pp. 1570-1580
-
-
Iland, H.J.1
Bradstock, K.2
Supple, S.G.3
-
32
-
-
84949228494
-
Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide
-
Shen Y, Fu YK, Zhu YM, et al. Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. EBioMedicine 2015; 2:563-571.
-
(2015)
EBioMedicine
, vol.2
, pp. 563-571
-
-
Shen, Y.1
Fu, Y.K.2
Zhu, Y.M.3
-
33
-
-
84946497114
-
Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California
-
Abrahao R, Ribeiro RC, Medeiros BC, et al. Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California. Cancer 2015; 121:3990-3997.
-
(2015)
Cancer
, vol.121
, pp. 3990-3997
-
-
Abrahao, R.1
Ribeiro, R.C.2
Medeiros, B.C.3
-
34
-
-
84855231183
-
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
-
McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012; 97:133-136.
-
(2012)
Haematologica
, vol.97
, pp. 133-136
-
-
McClellan, J.S.1
Kohrt, H.E.2
Coutre, S.3
-
35
-
-
0034124641
-
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia
-
Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108:689-695.
-
(2000)
Br J Haematol
, vol.108
, pp. 689-695
-
-
Di Bona, E.1
Avvisati, G.2
Castaman, G.3
-
36
-
-
79961092821
-
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
-
Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254.
-
(2011)
Blood
, vol.118
, pp. 1248-1254
-
-
Park, J.H.1
Qiao, B.2
Panageas, K.S.3
-
37
-
-
84923673401
-
A multicenter experience from Lebanon in childhood and adolescent acute myeloid leukemia: High rate of early death in childhood acute promyelocytic leukemia
-
Farah RA, Horkos JG, Bustros YD, et al. A multicenter experience from lebanon in childhood and adolescent acute myeloid leukemia: high rate of early death in childhood acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 2015; 7:e2015012.
-
(2015)
Mediterr J Hematol Infect Dis
, vol.7
, pp. e2015012
-
-
Farah, R.A.1
Horkos, J.G.2
Bustros, Y.D.3
-
38
-
-
84880964268
-
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death
-
Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37:1004-1009.
-
(2013)
Leuk Res
, vol.37
, pp. 1004-1009
-
-
Altman, J.K.1
Rademaker, A.2
Cull, E.3
-
39
-
-
13244277933
-
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia
-
Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004; 2:1341-1350.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1341-1350
-
-
Tallman, M.S.1
Lefebvre, P.2
Baine, R.M.3
-
40
-
-
60549107175
-
Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies
-
Falanga A, Rickles FR. Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165-171.
-
(2007)
Hematology Am Soc Hematol Educ Program
, pp. 165-171
-
-
Falanga, A.1
Rickles, F.R.2
-
41
-
-
0034121403
-
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment
-
Zhao W, Wang X, Guo W, et al. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chin Med J (Engl) 2000; 113:236-240.
-
(2000)
Chin Med J (Engl)
, vol.113
, pp. 236-240
-
-
Zhao, W.1
Wang, X.2
Guo, W.3
-
42
-
-
43549105926
-
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
-
de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-3402.
-
(2008)
Blood
, vol.111
, pp. 3395-3402
-
-
Dela Serna, J.1
Montesinos, P.2
Vellenga, E.3
-
43
-
-
83555165967
-
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia
-
Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156:24-36.
-
(2012)
Br J Haematol
, vol.156
, pp. 24-36
-
-
Breen, K.A.1
Grimwade, D.2
Hunt, B.J.3
-
44
-
-
84897954186
-
The unique hemostatic dysfunction in acute promyelocytic leukemia
-
Kwaan HC. The unique hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2014; 40:332-336.
-
(2014)
Semin Thromb Hemost
, vol.40
, pp. 332-336
-
-
Kwaan, H.C.1
-
45
-
-
78149302864
-
Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia
-
Kwaan HC, Rego EM. Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 2010; 36:917-924.
-
(2010)
Semin Thromb Hemost
, vol.36
, pp. 917-924
-
-
Kwaan, H.C.1
Rego, E.M.2
-
46
-
-
84877927952
-
Increased promyelocytic-derived microparticles: A novel potential factor for coagulopathy in acute promyelocytic leukemia
-
Ma G, Liu F, Lv L, et al. Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 2013; 92:645-652.
-
(2013)
Ann Hematol
, vol.92
, pp. 645-652
-
-
Ma, G.1
Liu, F.2
Lv, L.3
-
47
-
-
84957457773
-
PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells
-
[Epub ahead of print]
-
Fang Y, Garnier D, Lee TH, et al. PML-RARa modulates the vascular signature of extracellular vesicles released by acute promyelocytic leukemia cells. Angiogenesis 2015. [Epub ahead of print]
-
(2015)
Angiogenesis
-
-
Fang, Y.1
Garnier, D.2
Lee, T.H.3
-
48
-
-
84901448095
-
Thrombo-hemorrhagic deaths in acute promyelocytic leukemia
-
Breccia M, Lo Coco F. Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thromb Res 2014; 133 (Suppl 2):S112-S116.
-
(2014)
Thromb Res
, vol.133
, pp. S112-S116
-
-
Breccia, M.1
Lo Coco, F.2
-
49
-
-
33845519881
-
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
-
Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21:79-83.
-
(2007)
Leukemia
, vol.21
, pp. 79-83
-
-
Breccia, M.1
Avvisati, G.2
Latagliata, R.3
-
50
-
-
84872819652
-
Acute promyelocytic leukemia-associated thrombosis
-
Chang H, Kuo MC, Shih LY, et al. Acute promyelocytic leukemia-associated thrombosis. Acta Haematol 2013; 130:1-6.
-
(2013)
Acta Haematol
, vol.130
, pp. 1-6
-
-
Chang, H.1
Kuo, M.C.2
Shih, L.Y.3
-
52
-
-
59449083213
-
Double hazard of thrombophilia and bleeding in leukemia
-
Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology Am Soc Hematol Educ Program 2007; 151-157.
-
(2007)
Hematology Am Soc Hematol Educ Program
, pp. 151-157
-
-
Kwaan, H.C.1
-
53
-
-
19344369975
-
Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-A single center experience in 34 patients
-
Dally N, Hoffman R, Haddad N, et al. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb Res 2005; 116:109-114.
-
(2005)
Thromb Res
, vol.116
, pp. 109-114
-
-
Dally, N.1
Hoffman, R.2
Haddad, N.3
-
54
-
-
84924967320
-
Thrombotic events in acute promyelocytic leukemia
-
Mitrovic M, Suvajdzic N, Elezovic I, et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res 2015; 135:588-593.
-
(2015)
Thromb Res
, vol.135
, pp. 588-593
-
-
Mitrovic, M.1
Suvajdzic, N.2
Elezovic, I.3
-
55
-
-
84867907562
-
-
National Comprehensive Cancer Network [Accessed 21 September 2015]
-
National Comprehensive Cancer Network. Acute myeloid leukemia (version 1.2015). http://www.nccn.org/professionals/physician-gls/pdf/aml.pdf. [Accessed 21 September 2015]
-
Acute Myeloid Leukemia (Version 1.2015)
-
-
-
56
-
-
61949441174
-
Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
-
Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-1891.
-
(2009)
Blood
, vol.113
, pp. 1875-1891
-
-
Sanz, M.A.1
Grimwade, D.2
Tallman, M.S.3
-
57
-
-
84861346428
-
Bleeding and thrombosis in acute promyelocytic leukemia
-
Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol 2012; 87:596-603.
-
(2012)
Am J Hematol
, vol.87
, pp. 596-603
-
-
Choudhry, A.1
DeLoughery, T.G.2
-
58
-
-
0025297555
-
Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia A GIMEMA retrospective study in 268 consecutive patients
-
Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75:2112-2117.
-
(1990)
Blood
, vol.75
, pp. 2112-2117
-
-
Rodeghiero, F.1
Avvisati, G.2
Castaman, G.3
-
59
-
-
73949097021
-
How i treat acute promyelocytic leukemia
-
Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114:5126-5135.
-
(2009)
Blood
, vol.114
, pp. 5126-5135
-
-
Tallman, M.S.1
Altman, J.K.2
-
60
-
-
0026647140
-
The 'retinoic acid syndrome' in acute promyelocytic leukemia
-
Frankel SR, Eardley A, Lauwers G, et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117:292-296.
-
(1992)
Ann Intern Med
, vol.117
, pp. 292-296
-
-
Frankel, S.R.1
Eardley, A.2
Lauwers, G.3
-
61
-
-
59649106888
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
-
Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775-783.
-
(2009)
Blood
, vol.113
, pp. 775-783
-
-
Montesinos, P.1
Bergua, J.M.2
Vellenga, E.3
-
62
-
-
77954681398
-
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome
-
Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115:5137-5146.
-
(2010)
Blood
, vol.115
, pp. 5137-5146
-
-
Sanz, M.A.1
Montesinos, P.2
Rayon, C.3
-
63
-
-
68049090919
-
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients
-
Dai CW, Zhang GS, Shen JK, et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol 2009; 121:1-8.
-
(2009)
Acta Haematol
, vol.121
, pp. 1-8
-
-
Dai, C.W.1
Zhang, G.S.2
Shen, J.K.3
-
64
-
-
77958456360
-
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
-
Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751-3757.
-
(2010)
Blood
, vol.116
, pp. 3751-3757
-
-
Powell, B.L.1
Moser, B.2
Stock, W.3
-
65
-
-
77956251955
-
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term follow-up data
-
Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28:3866-3871.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3866-3871
-
-
Mathews, V.1
George, B.2
Chendamarai, E.3
-
66
-
-
84869773108
-
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia
-
Pei R, Cao J, Ma J, et al. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia. Hematology 2012; 17:311-316.
-
(2012)
Hematology
, vol.17
, pp. 311-316
-
-
Pei, R.1
Cao, J.2
Ma, J.3
-
67
-
-
84892940228
-
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: A multicenter randomized controlled trial
-
Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013; 31:4215-4221.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4215-4221
-
-
Zhu, H.H.1
Wu, D.P.2
Jin, J.3
-
68
-
-
85015142977
-
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up
-
[Epub ahead of print]
-
Aznab M, Rezaei M. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Hematol Oncol 2015. [Epub ahead of print]
-
(2015)
Hematol Oncol
-
-
Aznab, M.1
Rezaei, M.2
-
69
-
-
0027368561
-
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
-
European APL 91 Group
-
Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82:3241-3249.
-
(1993)
Blood
, vol.82
, pp. 3241-3249
-
-
Fenaux, P.1
Le Deley, M.C.2
Castaigne, S.3
-
70
-
-
0030610687
-
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II Clinical efficacy and pharmacokinetics in relapsed patients
-
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
-
(1997)
Blood
, vol.89
, pp. 3354-3360
-
-
Shen, Z.X.1
Chen, G.Q.2
Ni, J.H.3
-
71
-
-
11144355810
-
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
-
Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328-5335.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 5328-5335
-
-
Shen, Z.X.1
Shi, Z.Z.2
Fang, J.3
-
72
-
-
33645498328
-
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity
-
Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627-2632.
-
(2006)
Blood
, vol.107
, pp. 2627-2632
-
-
Mathews, V.1
George, B.2
Lakshmi, K.M.3
-
73
-
-
70349124202
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
-
Montesinos P, Diaz-Mediavilla J, Deben G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 2009; 94:1242-1249.
-
(2009)
Haematologica
, vol.94
, pp. 1242-1249
-
-
Montesinos, P.1
Diaz-Mediavilla, J.2
Deben, G.3
-
74
-
-
34247369329
-
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
-
Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24:5703-5710.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5703-5710
-
-
Ades, L.1
Chevret, S.2
Raffoux, E.3
-
75
-
-
84856501661
-
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
-
Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 2012; 97:227-234.
-
(2012)
Haematologica
, vol.97
, pp. 227-234
-
-
Iland, H.1
Bradstock, K.2
Seymour, J.3
-
76
-
-
84954529535
-
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A nonrandomised phase 2 trial
-
Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a nonrandomised phase 2 trial. Lancet Haematol 2015; 2:e357-e366.
-
(2015)
Lancet Haematol
, vol.2
, pp. e357-e366
-
-
Iland, H.J.1
Collins, M.2
Bradstock, K.3
-
77
-
-
84876120195
-
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial
-
Burnett AK, Hills RK, Grimwade D, et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 2013; 27:843-851.
-
(2013)
Leukemia
, vol.27
, pp. 843-851
-
-
Burnett, A.K.1
Hills, R.K.2
Grimwade, D.3
-
78
-
-
84906656419
-
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: Results from a randomized controlled trial
-
Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol 2014; 32:3729-3735.
-
(2014)
J Clin Oncol
, vol.32
, pp. 3729-3735
-
-
Shinagawa, K.1
Yanada, M.2
Sakura, T.3
-
79
-
-
84925539729
-
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia
-
Results from the SAL-AIDA2000 trial
-
Rollig C, Schafer-Eckardt K, Hanel M, et al. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. Ann Hematol 2015; 94:557-563.
-
(2015)
Ann Hematol
, vol.94
, pp. 557-563
-
-
Rollig, C.1
Schafer-Eckardt, K.2
Hanel, M.3
-
80
-
-
84939490795
-
Safety and tolerability of the combination of ATRA \+ arsenic trioxide (ATO) \+ gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial
-
7016
-
Lancet JE, Othus M, DeAngelo DJ, et al. Safety and tolerability of the combination of ATRA \+ arsenic trioxide (ATO) \+ gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): initial report of the SWOG/Alliance/ECOG S0535 trial. J Clin Oncol 2015; 33 (suppl): Abstract# 7016.
-
(2015)
J Clin Oncol
, vol.33
-
-
Lancet, J.E.1
Othus, M.2
DeAngelo, D.J.3
-
81
-
-
84880057409
-
The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission
-
Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev 2013; 3:CD009594.
-
(2013)
Cochrane Database Syst Rev
, vol.3
, pp. CD009594
-
-
Muchtar, E.1
Vidal, L.2
Ram, R.3
-
82
-
-
0030738326
-
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid
-
Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90:967-973.
-
(1997)
Blood
, vol.90
, pp. 967-973
-
-
Tobita, T.1
Takeshita, A.2
Kitamura, K.3
-
83
-
-
84928271904
-
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: Favorable outcomes with limited anthracycline exposure and shorter consolidation therapy
-
Leech M, Morris L, Stewart M, et al. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. Clin Lymphoma Myeloma Leuk 2015; 15:292-297.
-
(2015)
Clin Lymphoma Myeloma Leuk
, vol.15
, pp. 292-297
-
-
Leech, M.1
Morris, L.2
Stewart, M.3
-
84
-
-
84970930828
-
APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA
-
Burnett A RN, Hills R, Khwaja A, et al. APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA. Haematologica 2015; 100 (s1):334.
-
(2015)
Haematologica
, vol.100
, Issue.51
, pp. 334
-
-
Burnett, A.R.N.1
Hills, R.2
Khwaja, A.3
-
85
-
-
84952628453
-
Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States
-
[Epub ahead of print]
-
Tallman M, Lo-Coco F, Barnes G, et al. Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States. Clin Lymphoma Myeloma Leuk 2015. [Epub ahead of print]
-
(2015)
Clin Lymphoma Myeloma Leuk
-
-
Tallman, M.1
Lo-Coco, F.2
Barnes, G.3
-
86
-
-
84945301468
-
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia
-
[Epub ahead of print]
-
Jiang H, LiangGW, Huang XJ, et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Leuk Res 2015. [Epub ahead of print]
-
(2015)
Leuk Res
-
-
Jiang, H.1
Liang, G.W.2
Huang, X.J.3
-
87
-
-
84872290502
-
Outcome of elderly patients with acute promyelocytic leukemia: Results of the German Acute Myeloid Leukemia Cooperative Group
-
Lengfelder E, Hanfstein B, Haferlach C, et al. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 2013; 92:41-52.
-
(2013)
Ann Hematol
, vol.92
, pp. 41-52
-
-
Lengfelder, E.1
Hanfstein, B.2
Haferlach, C.3
|